At $144.30 Price, Jazz Pharmaceuticals plc (JAZZ) Is Sitting And Waiting – Stocks Register
Home  »  Business   »  At $144.30 Price, Jazz Pharmaceuticals plc (JAZZ) ...

At $144.30 Price, Jazz Pharmaceuticals plc (JAZZ) Is Sitting And Waiting

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) concluded the trading at $144.30 on Friday, January 14 with a rise of 0.49% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $143.59 and 5Y monthly beta was reading 0.94 with its price kept floating in the range of $143.72 and $145.885 on the day. Considering stock’s 52-week price range provides that JAZZ hit a high price of $189.00 and saw its price falling to a low level of $117.64 during that period. Over a period of past 1-month, stock came adding 18.54% in its value.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


With its current market valuation of $8.76 billion, Jazz Pharmaceuticals plc is set to declare its quarterly results on Feb 21, 2022 – Feb 25, 2022. Analysts are in estimates of $3.54 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to $15.63 for 2021 with estimates of that growing to $17.46 in next year. These estimates are suggesting current year growth of 25.40% for EPS and 11.70% growth next year.

Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $867.48 million. They suggested that in the process company could generate revenue of as low as $833.47 million which could climb up to $896.73 million to hit a high. The average estimate is representing an increase of 30.30% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $3.07 billion in 2021, which will be 30.00% more from revenue generated by the company last year.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with 1 upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review JAZZ stock’s current outlook then short term indicators are assigning it an average of 50% Buy, while medium term indicators are categorizing the stock at an average of 50% Sell. Long term indicators are suggesting an average of Hold for it.

According to ratings assigned by 20 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 2 of them are recommending Jazz Pharmaceuticals plc (JAZZ) as a Hold, while 17 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 1, whereas 0 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.

Digging deeper we become aware of the PEG ratio of the JAZZ stock which is currently positioned at 0. It further provides that stock’s current price level is 8.97% away from its 20-day simple moving average and is 10.97% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 66.37 while volatility remained at 3.55% over the past week which changes to 2.96% when measuring it over the past month. Beta is valued at 0.93, while measure of average true range or ATR is currently at 4.33. In predicting price targets of as low as $172.00 and as high as $250.00, analysts are in agreement on assigning the stock over the next 12 months average price target of $200.74. Stock’s current price level is -19.2% above from estimated low price target while it is -73.25% below the estimated high; and even if the JAZZ’s share succeeded to reach the median price of $202.00, then the outlook of -39.99% could come to the excitement of the investors.

In comparing Jazz Pharmaceuticals plc (JAZZ)’s stock with other industry players reveals that stock’s current price change of 0.49% and that of -13.96% over the past 12 months is in competing position with that of Johnson & Johnson (JNJ) which saw its stock price fall by -0.55% in the last trading and went through an increase of 4.70% in past 12-month trading. Industry’s another major player Pfizer Inc. (PFE) has fall -1.06% down in previous session, but over the past year has faced a rise of 49.73%, while Merck & Co. Inc. (MRK) was also up 0.07% however its price remained floating in the green at 2.36% over the same period. Jazz Pharmaceuticals plc has a P/E ratio of 0 against that of Johnson & Johnson’s 25.09 while Pfizer Inc. is showing 16.56 for the same. On the other hand, the S&P 500 Index was up 0.08% in the last trading session while the Dow Jones Industrial closed the session lower at -0.56%.

Having a second look at Jazz Pharmaceuticals plc (NASDAQ:JAZZ) provides that stock’s average daily trading volume for 3 months was 604.75K. Number of outstanding shares of the stock stood at 61.28 million.

>> 7 Top Picks for the Post-Pandemic Economy <<

The percentage of outstanding shares held by the insiders is 2.70% while it is 97.30% for the institutional holders. Addition of 13.27% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Videos

Related Posts



Download Free eBook For


100% free. stop anytime no spam